Naxus® positive clinical results on its contribution towards an effective vaccination in elderly individuals

Maastricht, The Netherlands, September 8th, 2021

Press release
The results of the recent clinical trial displayed the significant benefits of Naxus® towards  the efficacy of vaccines . Naxus® led to a significant positive changes in parameters such as, cytokine production, microbiota composition, and fecal PH compared to other non-digestible polysaccharides. 

Arabinoxilan vaccine efficiency.j

The Clinical Benefits of Naxus®

Immunosenescence is the process of deterioration of immune system functionality, mostly present in the elderly. Effective vaccination of the older adult is therefore a rising concern and a point to consider. BioActor has published the results of its recent clinical trial on Naxus®, an arabinoxylan extract from wheat endosperm on vaccination efficiency in Nutrients (Laue et al. 2021). Naxus® was compared to other non-digestible polysaccharides (NSPs): Wellmune®, Oatwell®, a beta-glucan from shiitake and exopolysaccharide preparation from L. Mucosae. NSPs are known for their promising effects on improving the immune response. From all investigated products, daily supplementation of Naxus® improved vaccination efficiency most effectively. Naxus® was further found to be safe, tolerable and feasible as a supplement.

The participants that completed the randomized, placebo-controlled, double-blind study were 231 of 239 subjects. Participants where split into six groups, each consuming a different non-digestible polysaccharide or control: Naxus®, Oatwell®, Wellmune®, a beta-glucan preparation from shiitake prepared according to a pre-specified procedure or an exopolysaccharide preparation from L. Mucosae for the duration of 5 weeks. The study showed significant beneficial changes in the Naxus® group compared to control in several parameters such as, cytokine production, microbiota composition and fecal pH.

Some of these beneficial changes could be linked with the significant increase in the abundance of Bifidobacterium in the gut that Naxus® demonstrated in the study. This increase is associated with a reduced infection, duration of influenza and severity of the common cold. Furthermore, an increase in IFN-γ was observed as a result of Naxus® consumption. IFN-y cytokines are produced by natural killer cells, which function as the first in line of defense against viral infections.

The researchers conclude that Naxus® is the most effective compound tested, compared to other NSPs, in this study to promote an adjuvant effect on the immune response to vaccination.
Although lack of understanding of the underlying mechanism, strong immunomodulatory are likely to explain the effect. Previous In-vitro work already demonstrated convincing links between the innate immune system and Naxus®. An enhanced vigilance of the immune system could therefore be the key to an explanation of the vaccination efficiency.

In conclusion, the findings in this study show a valuable contribution of Naxus® to our body, functioning as a prebiotic and enhancing protection against unwanted intruders!

BioActor’s Chief Scientific Officer, Yala Stevens says: “I am very happy with the publication of the vaccination trial, as it is the culmination of a great effort and collaboration involving multiple partners. These interesting results I believe are also very relevant and deserve to be shared within the scientific community and beyond.”

Naxus® can be applied in various finished dosage forms, including bars, granola, flapjacks, capsules, stick packs, scoopable powder.

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact us via info@bioactor.com for more information on the possibilities Naxus® has to offer.
Further information can be found on: www.naxus.nl